Performance and Prospects of [68Ga]Ga-FAPI PET/CT Scans in Lung Cancer

Borgonje, Paula E.; Andrews, Louise M.; Herder, Gerarda J.M.; Klerk, John M. H. de

doi:10.3390/cancers14225566

Cited by 11 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the radiolabeled FAP inhibitors applied to PET imaging can potentially monitor therapeutic response to FAP-targeted CAR T-cell therapy, reducing the limitations of CAR T-cell therapy. In addition, the therapeutic effect of CART is also gradually established in HCC and glioblastoma [359][360][361][362][363]. Unfortunately, it has been observed that using FAP-targeted CAR T cells to target subcutaneous tumors in mice led to deadly myelotoxicity and cachexia [224].…”

Section: Targeting Cafs Via Biomarkersmentioning

confidence: 99%

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Zhang,

Yue,

Chen

et al. 2023

Mol Cancer

102

View full text Add to dashboard Cite

Despite centuries since the discovery and study of cancer, cancer is still a lethal and intractable health issue worldwide. Cancer-associated fibroblasts (CAFs) have gained much attention as a pivotal component of the tumor microenvironment. The versatility and sophisticated mechanisms of CAFs in facilitating cancer progression have been elucidated extensively, including promoting cancer angiogenesis and metastasis, inducing drug resistance, reshaping the extracellular matrix, and developing an immunosuppressive microenvironment. Owing to their robust tumor-promoting function, CAFs are considered a promising target for oncotherapy. However, CAFs are a highly heterogeneous group of cells. Some subpopulations exert an inhibitory role in tumor growth, which implies that CAF-targeting approaches must be more precise and individualized. This review comprehensively summarize the origin, phenotypical, and functional heterogeneity of CAFs. More importantly, we underscore advances in strategies and clinical trials to target CAF in various cancers, and we also summarize progressions of CAF in cancer immunotherapy.

show abstract

Section: Targeting Cafs Via Biomarkersmentioning

confidence: 99%

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Zhang,

Yue,

Chen

et al. 2023

Mol Cancer

102

View full text Add to dashboard Cite

show abstract

“…Furthermore, the brain, a common site for lung cancer metastasis, exhibits high 18 F-FDG uptake, limiting the effectiveness of contrast agents ( 19 , 20 ). The 68 Ga-FAPI PET/CT has garnered considerable interest for its superior tumor-to-background ratio across various cancers relative to 18 F-FDG PET/CT ( 21 ). Studies comparing these two imaging modalities have demonstrated that 68 Ga-FAPI-04 PET/CT identifies more lesions in NSCLC and achieves greater diagnostic accuracy than 18 F-FDG PET/CT ( 22 ).…”

Section: Discussionmentioning

confidence: 99%

“…effectiveness of contrast agents(19,20). The 68 Ga-FAPI PET/CT has garnered considerable interest for its superior tumor-tobackground ratio across various cancers relative to 18 F-FDG PET/ CT(21). Studies comparing these two imaging modalities have…”

mentioning

confidence: 99%

A retrospective study of 68Ga-FAPI PET/CT in differentiating the nature of pulmonary lesions

Xie,

Tang,

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

PurposeThis study aimed to investigate the characteristics of various pulmonary lesions as revealed by 68Ga-FAPI PET/CT and to determine the utility of 68Ga-FAPI PET/CT in distinguishing the nature of these pulmonary lesions.MethodsA retrospective analysis was conducted on 99 patients with pulmonary lesions, who were categorized into three distinct groups: primary lung tumors (G1), metastatic lung tumors (G2), and benign lesions (G3). Each participant underwent a 68Ga-FAPI PET/CT scan. Among these groups, variables such as the Tumor/Background Ratio (TBR), Maximum Standardized Uptake Value (SUVmax), and the true positive rate of the lesions were compared. Furthermore, the FAPI uptake in nodular-like pulmonary lesions (d<3cm) and those with irregular borders was evaluated across the groups. A correlation analysis sought to understand the relationship between FAPI uptake in primary and pulmonary metastatic lesions.ResultsThe study’s participants were composed of 52 males and 47 females, with an average age of 56.8 ± 13.2 years. A higher uptake and detection rate for pulmonary lesions were exhibited by Group G1 compared to the other groups (SUVmax [G1 vs. G2 vs. G3: 9.1 ± 4.1 vs. 6.1 ± 4.1 vs. 5.3 ± 5.8], P<0.05; TBR [G1 vs. G2 vs. G3: 6.2 ± 2.4 vs. 4.1 ± 2.2 vs. 3.2 ± 2.7], P<0.01; true positive rate 95.1% vs. 88% vs. 75.6%]. In nodular-like lung lesions smaller than 3 cm, G1 showed a significantly higher FAPI uptake compared to G2 and G3 (SUVmax [G1 vs. G2 vs. G3: 8.8 ± 4.3 vs. 5.2 ± 3.2 vs. 4.9 ± 6.1], P<0.01; TBR [G1 vs. G2 vs. G3: 5.7 ± 2.7 vs. 3.7 ± 2.1 vs. 3.3 ± 4.4], P<0.05). Both G1 and G2 demonstrated significantly elevated FAPI agent activity in irregular-bordered pulmonary lesions when compared to G3 (SUVmax [G1 vs. G2 vs. G3: 10.9 ± 3.3 vs. 8.5 ± 2.7 vs. 4.6 ± 2.7], P<0.01; TBR [G1 vs. G2 vs. G3: 7.2 ± 2.1 vs. 6.4 ± 1.3 vs. 3.2 ± 2.4], P<0.01). A positive correlation was identified between the level of 68Ga-FAPI uptake in primary lesions and the uptake in pulmonary metastatic lesions within G2 (r=0.856, P<0.05).Conclusion68Ga-FAPI PET/CT imaging proves to be of significant value in the evaluation of pulmonary lesions, offering distinctive insights into their nature.

show abstract

“…The utilization of the Gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) radiotracer, which is a transmembrane peptidase that is upregulated in cancer-associated fibroblasts (CAFs), has the potential to address the difficulty posed by tumors with low 18F-FDG avidity [6,7]. Indeed, several research studies have explored the potential use of 68Ga-FAPI for the detection and assessment of rare malignancies [8,9].…”

Section: Introductionmentioning

confidence: 99%

Gallium-68-Labeled Fibroblast Activation Protein Inhibitor as an Alternative Radiotracer to Fluorine 18-Fluorodeoxyglucose: A Case Report of Rare Pulmonary Colloid Adenocarcinoma Diagnosed by PET/CT

Mansour,

Obeidat,

Al-Adhami

et al. 2024

Cureus

View full text Add to dashboard Cite

Colloid pulmonary adenocarcinoma represents a seldom encountered neoplasm in clinical practice. The diagnostic process for this rare neoplasm is complicated by its infrequency and the limited understanding of its specific molecular imaging characteristics. We report a 65-year-old male who was diagnosed with pulmonary colloid mucinous cystadenocarcinoma. Fluorine 18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) was conducted for initial evaluation. The scan showed mild 18F-FDG expression at the primary tumor site, and several non-18F-FDG-avid mediastinal and paraesophageal lymph nodes exhibited suspicious morphologic features. Owing to the ongoing atrial fibrillation, initial histopathological confirmation of the primary tumor mass carries a sense of risk, prompting the imperative for cardiological assessment before proceeding. Instead, Gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT was performed, expecting this to be more informative in terms of malignancy potential than 18F-FDG PET in colloid mucinous histology. A scan revealed moderate 68Ga-FAPI expression at the primary tumor site but unremarkable 68Ga-FAPI expression at the questionable lymph node. Subsequently, a biopsy from a mediastinal node (left para-aortic) lymph node via endobronchial ultrasound (EUS) showed benign findings. The patient was treated with concurrent chemoradiation. This case underscores the vital role that 68Ga-FAPI PET/CT can play in specific cases of rare cancers, especially when invasive testing for tissue biopsy is not feasible.

show abstract

Performance and Prospects of [68Ga]Ga-FAPI PET/CT Scans in Lung Cancer

Cited by 11 publications

References 48 publications

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

A retrospective study of 68Ga-FAPI PET/CT in differentiating the nature of pulmonary lesions

Gallium-68-Labeled Fibroblast Activation Protein Inhibitor as an Alternative Radiotracer to Fluorine 18-Fluorodeoxyglucose: A Case Report of Rare Pulmonary Colloid Adenocarcinoma Diagnosed by PET/CT

Contact Info

Product

Resources

About